Prothya Biosolutions

Executive Summary

Prothya Biosolutions is a private Belgium-based company founded in 2012 that provides high-quality services and plasma-derived medicinal products to healthcare organizations worldwide. The company operates in the biologics sector, focusing on essential plasma-derived medicines for patients with chronic and life-threatening conditions. By leveraging expertise in plasma fractionation and supply chain management, Prothya aims to create value for its partners while sustaining the health of patients dependent on these therapies. The company's Amsterdam headquarters and operational footprint support a global reach, though financial details and product pipeline specifics remain undisclosed due to its private status.

Upcoming Catalysts (preview)

• Q4 2026Regulatory approval for new plasma-derived product in Europe60% success
• Q2 2027Expansion of plasma collection capacity through new partnerships50% success
• TBDPotential strategic acquisition or licensing deal to broaden portfolio40% success